New research article demonstrates the potential for lab-on-chip catalysis using Attana technology
A recent article published in RSC Advances (Royal Society of Chemistry) illustrates how Attana gold coated surfaces functionalized with a combination of polyethyleneimine and palladium nanoparticles have been used as efficient catalysts and the potential for using this approach in lab-on-a-chip-based synthesis applications using the Attana Quartz Crystal Microbalance (QCM) system.
Attana technology has been applied by the team of Prof Ian Nicholls at Linnaeus University,
in their development of a flow microreactor for catalyzes of a series of Suzuki reactions. The recently published RSC Advance article is titled, “Palladium nanoparticles immobilized on polyethylenimine-derivatized gold surfaces for catalysis of Suzuki reactions: development and application in a lab-on-a-chip context” (https://pubs-rsc-org.proxy.lnu.se/en/content/articlelanding/2021/RA/D1RA06851B).
Nanostructures and nanoparticles have been used in several applications including catalysis, separation technologies and medical devices. Recently, Nicholls’ group has demonstrated that the immobilization of PEI hydrogels on metallic surfaces for use as antifouling surfaces. In addition, others have studied the potential of surface-bound palladium nanoparticles for use as catalysts of C–C coupling reactions.
The importance of the publication is that it illustrates that a gold surface bound hyperbranched poly-ethyleneimine films decorated with palladium nano-particles format using the QCM instrument had catalytic efficiency and stability, and this opens for the use of this approach in lab-on-a-chip-based synthesis applications.
Palladium immobilization on polyethyleneimine coated Au/ quartz surfaces: Scheme showing the method employed and scanning electron micrographs of (A) gold surface, (B) polyethyleneimine (PEI) film and (C) PEI-supported palladium particles fabricated on Au/quartz surfaces.
This work was performed as part of the Swedish Knowledge Foundation financed project “BIO-QC: Quality Control and Purification for New Biological Drugs” (grant number 20170059), where Attana is part.
The full publication can be found here.
To view all publications enabled by Attana, follow this link.
For more information, please contact:
Teodor Aastrup, CEO
teodor.aastrup@attana.com
+46 (0)8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.
About Attana
Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com
Tags:
